Affymax (AFFY) and Takeda Agree to Suspend Clinical Development of Hematide(TM)
More News related to AFFY
- Affymax (AFFY) Announces Data Monitoring Committee Completes Review of Phase 3 Hematide Program; Trials Support Continuation of Studies
- Affymax Announces Another Favorable Data Monitoring Committee Review of Phase 3 Hematide Program
- Affymax, Inc. (AFFY) Executive Officer to Ring the NASDAQ Stock Market Closing Bell
- Affymax Completes Enrollment in Phase 3 Program for Hematide in Chronic Renal Failure with Completion of Enrollment in EMERALD 2, the Final of Four Phase 3 Clinical Trials of Hematide(TM)
- Affymax to Present at Lazard Capital Markets Conference
More News related to Corporate News
- The Hartford (HIG) Talks About Its Highly Rated CMBS Portfolio
- PepsiCo (PEP) to Invest $3 Billion in Mexico Operations
- Quicksilver Resources (KWK) Announces '09 Capital Budget
- Cosi, Inc. (COSI) Forms Special Committee to Review Strategic Alternatives
- Par Pharmaceutical (PRX) Halts Shipments of of Budesonide Inhalation Suspension
Affymax, Inc. (Nasdaq: AFFY) and Takeda Pharmaceutical Company Limited today announced their agreement to suspend co-development of Hematide(TM) to treat chemotherapy-induced anemia and to focus all development efforts for Hematide(TM) on the treatment of chronic kidney disease related anemia.
Takeda and Affymax continue to be encouraged by the potential of bringing Hematide to the millions of chronic kidney disease patients suffering from anemia and believe this represents a significant opportunity for the two companies.
Takeda has been conducting Phase I clinical studies of Hematide(TM) for the treatment of chemotherapy-induced anemia in the U.S. and Japan. However, the companies have decided to suspend development of Hematide in oncology and not to enroll new patients in the ongoing Phase I clinical trial of the product in chemotherapy-induced anemia given the uncertain regulatory landscapes for erythropoiesis-stimulating agents in oncology indications, despite the potential for Hematide in this indication.
Affymax, Inc., a biopharmaceutical company, engages in the development of peptide-based drug candidates to enhance the treatment of serious and life-threatening conditions.
Related Categories
Corporate NewsStocks Mentioned
-0.76Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
